The fund has exact preference in a number of founders of portfolio startups. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Capricor Therapeutics, 4D Molecular Therapeutics, Exonics Therapeutics Among the most successful fund investment fields, there are Medical Device, Genetics.
The top amount of exits for fund were in 2019. The high activity for fund was in 2019. The fund is generally included in less than 2 deals every year. The real fund results show that this Corporate Investor is 30 percentage points more often commits exit comparing to other companies. This CureDuchenne Ventures works on 21 percentage points more the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The overall number of key employees were 3.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the CureDuchenne Ventures, startups are often financed by Tavistock Life Sciences, Takeda Pharmaceutical, Moore Venture Partners. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, Logos Capital, Viking Global Investors. In the next rounds fund is usually obtained by The Column Group, National Institutes of Health.
|Batshit Crazy Ventures||Boulder, Colorado, United States|
|BlueGem Capital Partners||England, London, United Kingdom|
|ChemRar Ltd||Khimki, Moscow Oblast, Russia|
|Clinton Global Initiative||New York, New York, United States|
|Fischer Pharmaceutical Laboratories Ltd||Israel, Tel Aviv, Tel Aviv District|
|Groupe ADP||France, Ile-de-France, Paris|
|Gunosy||Chiba, Japan, Minato|
|Hongrui Touzi||China, Jiading, Shanghai|
|Inner Mongolia Kenuohuagai Investment Management||-|
|Link11||Frankfurt, Germany, Hessen|
|Nishi-Chugoku||Japan, Shimonoseki, Yamaguchi Prefecture|
|Panorama Point Partners||Nebraska, Omaha, United States|
|Pivotal Group||Arizona, Phoenix, United States|
|Prehype||New York, New York, United States|
|Sipadan Capital, LLC||New York, New York, United States|
|Strata Credit Union||Bakersfield, California, United States|
|Taixiang Investment Management||China, Ningbo, Zhejiang|
|Yifeng Investment||China, Shanghai|
|$75M||07 Jun 2022||Hatfield, Pennsylvania, United States|
|$1M||22 Dec 2021||New York, New York, United States|
|$112M||05 Aug 2021||Oxford, England, United Kingdom|
|$10M||20 Apr 2021||Hatfield, Pennsylvania, United States|
|$116M||31 Mar 2021||Boston, Massachusetts, United States|
|$45M||09 Dec 2020||Oxford, England, United Kingdom|
|$95M||08 Dec 2020||Boulder, Colorado, United States|
|10 Nov 2020||British Columbia|
|$1M||23 Apr 2020||Seattle, Washington, United States|
– Entrada Therapeutics from Boston develops intracellular biologics to treat devastating diseases.
– The company closed a $116m Series B financing.
– The round was led by Wellington Management Company and joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority (“QIA”), Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures and one undisclosed global investment firm.
– Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital also participated in the financing.
– The new investment will be used to advance its pipeline to the clinic.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.